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EVIDENCE-BASED ANSWER
A
 Ureteral calculi: What should 
you consider before intervening?
Evidence summary 
A meta-analysis of 5 prospective cohort stud-
ies evaluated the rate of spontaneous passage 
of ureteral calculi according to size. Calculi 
smaller than 5 mm passed spontaneously in 
68% of patients (5 studies, N=224). Calculi be-
tween 5 and 10 mm passed spontaneously in 
47% of patients (3 studies, N=104).1 
A prospective cohort study evaluated 
spontaneous passage rates of ureteral calculi 
by size in 172 patients who were diagnosed by 
unenhanced helical computed tomography.2 
Investigators found spontaneous passage 
rates of 87% for 1-mm calculi, 76% for 2- to 
4-mm calculi, 60% for 5- to 7-mm calculi, 
48% for 7- to 9-mm calculi, and 25% for cal-
culi larger than 9 mm. 
Spontaneous passage rates diff ered sig-
nifi cantly for calculi 1 to 4 mm in size com-
pared with calculi 5 to 7 mm in size (P<.001) 
and for calculi 5 to 7 mm in size compared 
with calculi 8 mm or larger (P<.001). Calculi 
in either the distal ureter or ureterovesicular 
junction were more likely to pass that those 
in the mid- or proximal ureter (75% to 79% vs 
48% to 60%; P<.001).
Most smaller calculi pass in 4 to 6 weeks
Another prospective cohort study (N=75) 
found that most calculi pass spontaneously 
within 4 to 6 weeks. In 95% of patients, cal-
culi passed within 31 days (2 mm or smaller), 
40 days  (2-4 mm), or 39 days (4-6 mm).3
Some cases require prompt surgery
Th e American Urological Association (AUA) 
expert panel recommends early surgical in-
tervention, regardless of calculus size, under 
the following circumstances: obstruction 
with high-grade hydronephrosis, infection, 
impending renal deterioration, intractable 
pain, nausea and vomiting, or obstruction in 
a solitary or transplanted kidney.1
Medical expulsion therapy trumps 
waiting for distal calculi to pass
A meta-analysis comparing rates of calcu-
lus passage found that medical expulsion 
therapy was more eff ective than expectant 
management for patients with distal ureteral 
calculi. Sixteen RCTs (N=1235) evaluated 
alpha-antagonists (mostly tamsulosin), and 
9 RCTs (N=686) evaluated nifedipine. Treat-
      the size of the calculi, their
       location, and complicating factors 
such as infection should all be considered. 
Most ureteral calculi smaller than 
5 mm pass spontaneously, as do approxi-
mately half of calculi between 5 and 10 mm. 
Calculi larger than 10 mm are unlikely to 
pass without intervention. Distal calculi are 
more likely to pass spontaneously than cal-
culi in mid- or proximal ureteral locations; 
most spontaneous passage occurs within 
4 to 6 weeks (strength of recommendation 
[SOR]: A, prospective cohort studies). 
All patients with calculi complicated by 
such factors as obstruction, infection, renal 
injury, or a single kidney require surgical 
consultation (SOR: C, expert opinion).
Medical expulsion therapy with alpha-
blockers (usually tamsulosin) and nifedipine 
improves passage rates, including for some 
calculi larger than 10 mm (SOR: A, meta-
analysis of prospective cohort studies).
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ment periods for medical expulsion therapy 
ranged from 30 to 60 days. 
Alpha-antagonists increased expulsion 
rates over expectant management for calculi 
ranging in size from 3 to 18 mm with a mean 
diameter greater than 5 mm (relative risk 
[RR]=1.59; 95% confi dence interval [CI], 1.44-
1.75; number needed to treat [NNT]=3). Th e 
mean time until passage ranged from 2.7 to 
14.2 days. Nifedipine also increased expulsion 
rates for calculi with a mean diameter larger 
than 5 mm, ranging in size from 3.9 to 12.8 mm 
(RR=1.50; 95% CI, 1.34-1.68; NNT=4).4 
Recommendations 
Th e Joint European Association of Urology/
AUA Nephrolithiasis Guideline Panel recom-
mends observation with periodic evaluation 
for patients newly diagnosed with ureteral 
calculi smaller than 10 mm.1 Patients may be 
off ered medical expulsion therapy to facili-
tate calculus passage. Surveillance should be 
maintained until calculi pass; intervention 
should be considered if calculi don’t pass 
spontaneously within about 30 days.
Th e Panel states that patients with ure-
teral calculi larger than 10 mm could be ob-
served (with or without medical expulsion 
therapy); however, most cases will require 
surgical intervention.1                          JFP
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